Aivita Biomedical, Inc., an Irvine, Calif.-based biotechnology company specializing in innovative stem cell applications, held the first closing of its $25m Series B-2 funding.
The first closing of $12.5m was led by Matthew Katz, founder and CEO of Verifi, Inc., a customized software solution that systematically identifies payment risk, who has been appointed to the company’s board of directors, with participation from other healthcare-focused venture capital firms. Katz is also the head of Zoo Station, his family office focused on investing in early stage startups.
Founded in 2016 by Dr. Hans S. Keirstead, Chairman and CEO, Aivita Biomedical is a company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. The company utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products.
FinSMEs
25/02/2020